1.91
-0.03 (-1.55%)
| Penutupan Terdahulu | 1.94 |
| Buka | 1.95 |
| Jumlah Dagangan | 15,497 |
| Purata Dagangan (3B) | 47,365 |
| Modal Pasaran | 89,979,336 |
| Harga / Jualan (P/S) | 1.08 |
| Harga / Buku (P/B) | 2.97 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 23 Jul 2025 - 28 Jul 2025 |
| Margin Operasi (TTM) | -17,082.39% |
| EPS Cair (TTM) | -0.740 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -87.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 36.60% |
| Nisbah Semasa (MRQ) | 2.30 |
| Aliran Tunai Operasi (OCF TTM) | -29.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.87 M |
| Pulangan Atas Aset (ROA TTM) | -21.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -55.21% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Adagene Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 3.5 |
| Purata | 1.00 |
|
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 4.70% |
| % Dimiliki oleh Institusi | 33.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Wuxi Apptec Co., Ltd. | 30 Sep 2024 | 3,982,902 |
| Mill Creek Capital Advisors, Llc | 31 Mar 2025 | 199,610 |
| Gordian Capital Singapore Pte Ltd | 31 Mar 2025 | 18,900 |
| Catalina Capital Group, Llc | 31 Mar 2025 | 0 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 7.00 (HC Wainwright & Co., 266.49%) | Beli |
| 7.00 (Leerink Partners, 266.49%) | Beli | |
| Median | 7.00 (266.49%) | |
| Purata | 7.00 (266.49%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 2.03 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 15 Aug 2025 | 7.00 (266.49%) | Beli | 1.69 |
| Leerink Partners | 06 Aug 2025 | 7.00 (266.49%) | Beli | 2.37 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Aug 2025 | Pengumuman | Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates |
| 15 Jul 2025 | Pengumuman | Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA |
| 08 Jul 2025 | Pengumuman | Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate |
| 01 Jul 2025 | Pengumuman | Adagene announces up to $25 million strategic investment from Sanofi |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |